Место оригинального питавастатина в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Заключение междисциплинарного Совета экспертов РКО, НОА, РосОКР, РАЭ - Научно-практический журнал Cardioсоматика Том 16, №1 (2025)

Место оригинального питавастатина в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Заключение междисциплинарного Совета экспертов РКО, НОА, РосОКР, РАЭ

Бубнова М.Г., Галявич А.С., Ежов М.В., Аронов Д.М., Виноградова Н.Н., Галстян Г.Р., Гуревич В.С., Карпов Ю.А., Козиолова Н.А., Космачева Е.Д., Матюшин Г.В., Сергиенко И.В., Филиппов А.Е., Халимов Ю.Ш. Место оригинального питавастатина в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Заключение междисциплинарного Совета экспертов Российского кардиологического общества, Национального общества по изучению атеросклероза, Российского общества кардиосоматической реабилитации и вторичной профилактики, Российской ассоциации эндокринологов // CardioСоматика. 2025. Т. 16, № 1. С. 5–20. DOI: 10.17816/CS676903 EDN: PMQYMM

________________________________________________

Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov IuSh. The Place of Original Pitavastatin in Primary and Secondary Prevention of Cardiovascular Diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. CardioSomatics. 2025;16(1):5–20. DOI: 10.17816/CS676903 EDN: PMQYMM

Читать PDF

Аннотация

В представленном экспертном документе обсуждается высокая распространённость гиперхолестеринемии (ГХС) в России. Указывается на недостаточное применение липидснижающей терапии как в первичной, так и во вторичной профилактике. Серьёзной проблемой в реальной клинической практике остаются недостижение целевого уровня холестерина (ХС) липопротеидов низкой плотности и невысокая приверженность (особенно долгосрочная) пациентов принимаемым гиполипидемическим препаратам. Статины представляют собой класс широко назначаемых гиполипидемических средств, которые являются препаратами первого выбора в лечении ГХС и комбинированной гиперлипидемии с доказанной эффективностью в профилактике атеросклеротических сердечно-сосудистых заболеваний. В данном экспертном документе на примере оригинального питавастатина убедительно показаны не только возможности препарата в снижении атерогенных липидов и липопротеидов плазмы крови, но и клиническая эффективность в первичной и вторичной профилактике сердечно-сосудистых осложнений. При этом подчёркиваются уникальное влияние питавастатина на повышение низкого уровня ХС липопротеидов высокой плотности, доказанная антиатеросклеротическая активность и широкий спектр положительных плейотропных эффектов, которые усиливают его антиатерогенное воздействие. Присущий питавастатину низкий риск лекарственных взаимодействий подчёркивает высокую безопасность при длительном приёме и хорошую переносимость. Всё вышесказанное даёт основания рассматривать оригинальный питавастатин как препарат выбора для широкого круга пациентов.
Настоящая статья ранее опубликована как: Бубнова М.Г., Галявич А.С., Ежов М.В., Аронов Д.М., Виноградова Н.Н., Галстян Г.Р., Гуревич В.С., Карпов Ю.А., Козиолова Н.А., Космачева Е.Д., Матюшин Г.В., Сергиенко И.В., Филиппов А.Е., Халимов Ю.Ш. Заключение междисциплинарного Совета экспертов: место оригинального питавастатина в первичной и вторичной профилактике сердечно-сосудистых заболеваний // Российский кардиологический журнал. 2024. Т. 29, № 11. С. 6148. doi: 10.15829/1560-4071-2024-6148 EDN: PSIJPF
Публикация статьи осуществлена с согласия авторского коллектива, редакционной коллегии журнала «Российский кардиологический журнал» и не противоречит лицензии Creative Commons Attribution 4.0 License.

Ключевые слова: атеросклероз, сердечно-сосудистые заболевания, профилактика, гиполипидемическая терапия, статины, питавастатин

________________________________________________

The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients.
This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF
The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.

Keywords: atherosclerosis, cardiovascular diseases, prevention, lipid-lowering therapy, statins, pitavastatin

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791. doi: 10.15829/1728-8800-2023-3791 EDN: DGYJLA
2. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30. doi: 10.1093/eurheartj/ehz962
3. Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of lipid‑lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Russian Journal of Cardiology. 2022;27(5):5006. doi: 10.15829/1560-4071-2022-5006 EDN: HBBGKQ
4. Alieva AS, Usova EI, Zvartau NE, Shlyakhto EV. Implementation study to introduce clinical guidelines on lipid metabolism disorders into routine practice: results of the first stage. Russian Journal of Cardiology. 2024;29(1):5724. doi: 10.15829/1560-4071-2024-5724 EDN: ADVLHL
5. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. doi: 10.15829/1560-4071-2023-5471 EDN: YVZOWJ
6. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi: 10.1093/eurheartj/ehz455
7. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. doi: 10.1093/eurheartj/ehab4847-9
8. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta‑analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28. doi: 10.1016/j.ahj.2018.12.007
9. Singh BM, Lamichhane HK, Srivatsa SS, et al. Role of statins in the primary prevention of atherosclerotic cardiovascular disease and mortality in the population with mean cholesterol in the near-optimal to borderline high range: a systematic review and meta-analysis. Adv Prev Med. 2020;2020:6617905. doi: 10.1155/2020/6617905
10. Ma W, Pan Q, Pan D, et al. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:713007. doi: 10.3389/fphar.2021.713007
11. Banach M, Surma S. A look to the past — what has had the biggest impact on lipids in the last four decades? A personal perspective. Arch Med Sci. 2023;19(3):559–64. doi: 10.5114/aoms/166256
12. Banach M, Surma S, Toth PP. 2023: the year in cardiovascular disease — the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci. 2023;19(6):1602–15. doi: 10.5114/aoms/174743
13. Zhang Y, Vittinghoff E, Pletcher MJ, et al. Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events. J Am Coll Cardiol. 2019;74(3):330–41. doi: 10.1016/j.jacc.2019.03.529
14. Wang N, Woodward M, Huffman MD, Rodgers A. Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552. doi: 10.1161/CIRCOUTCOMES.121.008552
15. Bubnova MG, Ezhov MV, Aronov DM. Statins adherence and associated muscle symptoms in older coronary heart disease patients. Aging Pathobiology and Therapeutics. 2023;5(4):140–6. doi: 10.31491/APT.2023.12.125
16. Catapano AL. Pitavastatin: a different pharmacological profile. Clinical Lipidology. 2012;7(3 Suppl.1):3–9. doi: 10.2217/clp.12.21
17. Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and sel ect agents used in patients with cardiovascular disease. Circulation. 2016;134(21):е468–е495. doi: 10.1161/CIR.0000000000000456
18. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11. doi: 10.1016/j.phrs.2014.03.002
19. Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of Pitavastatin by formulation and ethnic group. Clin Drug Investig. 2011;31(10):735–43. doi: 10.2165/11592480-000000000-00000
20. Kastelein JJ, Braamskamp M. Pitavastatin: an overview of the LIVES study. Clin Lipidol. 2012;7(supp1):25–31. doi: 10.2217/CLP.12.24
21. Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J. 2014;78(3):679–84. doi: 10.1253/circj.cj-13-1216
22. Morgan RE, Campbell SE, Suehira K, et al. Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult Volunteers. J Acquir Immune Defic Syndr. 2012;60(2):158–64. doi: 10.1097/QAI.0b013e318251addb
23. Duggan ST. Pitavastatin A Review of its Use in the Management of Hypercholesterolaemia or Mixed Dyslipidaemia. Drugs. 2012;72(4):565–84. doi: 10.2165/11207180-000000000-00000
24. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG‑CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138–44. doi: 10.5551/jat1994.7.138
25. Gotto AM, Moon J. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia Expert Rev. Cardiovasc. Ther. 2010;8(8):1079–90. doi: 10.1586/erc.10.82
26. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(10):2755–64. doi: 10/1185/03007990903290886
27. Eriksson M, Budinski D, Hounslow N, et al. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011;28(9):811–23. doi: 10.1007/s12325-011-0056-7
28. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4(3):291–302. doi: 10.2217/clp.09.20
29. Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047–55. doi: 10.1111/j.1463-1326.2011.01477.x
30. Saito Y. Treatment Options for Hypercholesterolemia and Combined Dyslipidemia: Focus on Pitavastatin Clinical Medicine Insights. Therapeutics. 2011;3(3):517–25. doi: 10.4137/CMT.S6565
31. Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL). The PATROL Trial. Circ J. 2011;75(6):1493–505. doi: 10.1253/circj.CJ-10-1281
32. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345–52. doi: 10.1016/j.atherosclerosis.2008.02.008
33. Teramoto T. Pitavastatin: clinical effects fr om the LIVES Study. Atheroscler Suppl. 2011;12(3):285–8. doi: 10.1016/S1567-5688(11)70888-1
34. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Arzneimittelforschung. 2002;52(4):251–5. doi: 10.1055/s-0031-1299888
35. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem & Biophys Res Comm. 2004;324(2):835–9. doi: 10.1016/j.bbrc.2004.09.122
36. Fukutomi T, Takeda Y, Suzuki S, et al. High-density lipoprotein cholesterol andapolipoprotein A-I are persistently elevated during long‑term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol. 2010;141(3):320–2. doi: 10.1016/j.ijcard.2008.11.130
37. Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16(5):654–61. doi: 10.5551/jat.1719
38. Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol andadiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. J Cardiol. 2013;62(2):87–94. doi: 10.1016/j.jjcc.2013.03.008
39. Yamashita S, Tsubakio-Yamamoto K, Ohama T, et al. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb. 2010;17(5):436–51. doi: 10.5551/jat.5405
40. Kobayashi M, Gouda K, Chisaki I, et al. Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011;662(1–3):9–14. doi: 10.1016/j.ejphar.2011.04.043
41. Miyamoto-Sasaki M, Yasuda T, Monguchi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb. 2013;20(9):708–16. doi: 10.5551/jat.17210
42. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5):499–508. doi: 10.1001/jama.297.5.499
43. Kishida K, Funahashi T, Shimomura I. Importance of Assessing the Effect of Statins on the Function of High-Density Lipoproteins on Coronary Plaque. Cardiovascular & Haematological Disorders-Drug Targets. 2012;12(1):28–34. doi: 10.2174/1871529128023156
44. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New England Journal of Medicine. 2011;364(2):127–35. doi: 10.1056/NEJMoa1001689
45. Teramoto T, Urashima M, Sfornano H, et al.; LIVES Study Extension Group. A Large-Scale Survey on Cardio-Cerebrovascular Events During Pitavastatin (LIVALO Tablet) Therapy in Japanese Patients with Hypercholesterolernia — LiVALO Effectìveness and Safety Study Extension (LIVES Study Extension). Jpn Pharmacol Ther. 2011;39(9):789–803.
46. Miayauchi K, Daida H, Morimoto D, Hiro H, and Japan-ACS Investigators. Reverse vessel remodeling but not coronary plague regression could predict future cardiovascular events in ACS patients with intensive statin therapy — the extended JAPAN-ACS study. Circ J. 2012;76(4):825–32. doi: 10.1253/circj.CJ-12-0135
47. Chan P, Shao L, Tomlinson B, et al. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019;20(1):103–13. doi: 10.1080/14656566.2018.1544243
48. Kronenberg F, Mora S. Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. doi: 10.1093/eurheartj/ehac361
49. De Boer LM, Oorthuys AOJ, Wiegman A, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779–92. doi: 10.1093/eurjpc/zwab171
50. Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein (a) levels. Eur Heart J. 2020;41(24):2275–84. doi: 10.1093/eurheartj/ehz310
51. Wang X, Li J, Ju J, et al. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis. Pharmacological Research. 2021;163:105275. doi: 10.1016/j.phrs.2020.105275
52. Ezhov MV, Sergienko IV, Alekseeva IA. Pitavastatin (Livazo) in the treatment of dyslipidemia in routine clinical practice in russia. Russian programme "LEADER". The Journal of Atherosclerosis and Dyslipidemias. 2020;3(40):5–14. doi: 10.34687/2219-8202.JAD.2020.03.0001
53. Tsujita K, Yokote K, Ako J, et al. on behalf of the K-924 Clinical Study Group. Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial. J Atheroscler Thromb. 2023;30(11):1580–600. doi: 10.5551/jat.64006
54. Fici F, Faikoglu G, Tarim BA, et al. Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. High Blood Pressure Cardiovascular Prevention. 2022;29(2):137–44. doi: 10.1007/s40292-021-00496-0
55. Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. International J Cardiol. 2020;305:139–46. doi: 10.1016/j.ijcard.2020.01.006
56. Ikeda K, Takahashi T, Yamada H, et al. (for the PEACE Investigators). Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study. Eur J Prevent Cardiol. 2012;20(6):1069–79. doi: 10.1177/2047487312451539
57. Nakagomi A, Shibui T, Kohashi K, et al. Differential effects of atorvastatin and pitavastatin on inflammation, insulin resistance, and carotid intima‑media thickness in patients with dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158–71. doi: 10.5551/jat.29520
58. Takayama K, Taki W, Toma N, et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study — EPOCH-CAS Study. Cardiovasc Intervent Radiol. 2014;37(6):1436–43. doi: 10.1007/s00270-013-0813-x
59. Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51(4):365–71. doi: 10.1097/FJC.0b013e318165dcad
60. Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound — the TOGETHAR trial. Circ J. 2010;74(9):1922–8. doi: 10.1253/circj.cj-10-0038
61. Nozue T, Yamamoto S, Tohyama S, et al. Comparison of the effects of pitavastatin versus pravastatin on coronary artery plaque phenotype assessed by tissue characterization using serial virtual histology intravascular ultrasound. Heart Vessels. 2015;30(1):36–44. doi: 10.1007/s00380-013-0453-8
62. Hattori K, Ozaki Y, Ismail TF, et al. Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter–IVUS. J Am Coll Cardiol Img. 2012;5(2):169–77. doi: 10.1016/j.jcmg.2011.11.012
63. Matsushita K, Hibi K, Komura N, et al. Effects of 4 statins on regression of coronary plaque in acute coronary syndrome. Circ J. 2016;8(7):1634–43. doi: 10.1253/circj.CJ-15-1379
64. Nishiguchi T, Kubo T, Tanimoto T, et al. Effect of early pitavastatin therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. The ESCORT study. JACC Cardiovasc Imaging. 2018;11(6):829–38. doi: 10.1016/j.jcmg.2017.07.011
65. Hiro T, Kimura T, Morimoto T, et al. for the JAPAN-ACS Investigators. Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome A Multicenter Randomized Trial Evaluated by Volumetric Intravascular Ultrasound Using Pitavastatin Versus Atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J Am Coll Cardiol. 2009;54(4):293–302. doi: 10.1016/j.jacc.2009.04.033
66. Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J. 2007;71(11):1678–84. doi: 10.1253/circj.71.1678
67. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque — comparison with atorvastatin. Circ J. 2009;73(8):1466–72. doi: 10.1253/circj.CJ-08-1051
68. Taguchi I, Iimuro S, Iwata H, et al. High dose versus low‑dose pitavastatin in Japanese patients with stable coronary artery disease (REAL‑CAD): a randomized superiority trial. Circulation. 2018;137(19):1997–2009. doi: 10.1161/circulationaha.117.032615
69. Maruyama T, Takada M, Nishibori Y, et al Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J. 2011;75(8):1951–9. doi: 10.1253/circj.CJ-10-1163
70. Suh SY, Rha S-W, Ahn TH, et al. Long-term safety and efficacy of Pitavastatin in patients with acute myocardial infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS]). Am J Cardiol. 2011;108(11):1530–5. doi: 10.1016/j.amjcard.2011.07.009
71. Hagiwara N, Kawala-Wayanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38(29):2264–76. doi: 10.1093/eurheartj/ehx162
72. Takano H, Mizuma H, Kuwabara Y, et al. оn behalf of the PEARL Study Investigators. Effects of Pitavastatin in Japanese Patients With Chronic Heart Failure. The Pitavastatin Heart Failure Study (PEARL Study). Circ J. 2013;77(4):917–25. doi: 10.1253/circj.CJ-12-1062
73. Im J, Kawada‑Watanabe E, Yamaguchi J, et al. Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome. Scientific Reports. 2021;11(1):7480. doi: 10.1038/s41598-021-87098-x
74. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO tablet) — LIVALO effectiveness and safety (LIVES) study. Jpn Pharmacol Ther. 2008;36:709–31.
75. Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia. J Atheroscler Thromb. 2016;23(1):48–55. doi: 10.5551/jat.28753
76. Harada-Shiba M, Kastelein JJP, Hovingh GK, et al. Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe. J Atheroscler Thromb. 2018;25(5):422–9. doi: 10.5551/jat.42242
77. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. doi: 10.1093/eurheartj/ehv043
78. Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association’s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl.):S58–S71. doi: 10.1016/j.jacl.2014.03.004
79. Banach M, Rizzo M, Toth PP, et al. Statin intolerance — an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23. doi: 10.5114/aoms.2015.49807
80. Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study. J Clin Lipidol. 2014;8(1):69–76. doi: 10.1016/j.jacl.2013.10.006
81. Yee LL, Wright EA. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. Clin Ther. 2011;33(8):1023–42. doi: 10.1016/j.clinthera.2011.07.011
82. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Current Medical Research & Opinion. 2011;27(8):1551–62. doi: 10.1185/03007995.2011.589433
83. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8А):61C–68C. doi: 10.1016/j.amjcard.2005.12.011
84. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26–35. doi: 10.1016/j.clinthera.2006.01.005
85. Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open‑label, pilot study. Hepatol Res. 2011;41:1057–65. doi: 10.1111/j.1872-034X.2011.00849.x
86. Han KH, Rha SW, Kang HJ, et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol. 2012;6(4):340–51. doi: 10.1016/j.jacl.2012.01.009
87. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the Adverse Event Reporting System. Am J Cardiol. 2006;97(8A):32C–43C. doi: 10.1016/j.amjcard.2005.12.008
88. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease-subanalysis of the LIVALO effectiveness and safety (LIVES) study. J Atheroscler Thromb. 2010;17(6):601–9. doi: 10.551/jat.3764
89. Kang WC, Kim M, Park SM, et al. Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial. J Clin Med. 2020;9(11):3689. doi: 10.3390/jcm9113689
90. Abe M, Maruyama N, Maruyama T, et al. A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. J Atheroscler Thromb. 2015;22(12):1235–47. doi: 10.5551/jat.29264
91. Seo WW, Seo SI, Kim Y, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol. 2022;21(1):82. doi: 10.1186/s12933-022-01524-6
92. Trias F, Pinto X, Corbella E, et al. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc). 2022;158(11):531–9. doi: 10.1016/j.medcli.2021.06.018
93. Yoon D, Sheen SS, Lee S, et al. Statins and risk for new-onset diabetes mellitus. A real-world cohort study using a clinical research database. Medicine. 2016;95(46):e5429. doi: 10.1097/MD.0000000000005429
94. Na E, Cho S, Kim DJ, et al. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2020;19(1):1–11. doi: 10.1186/s12933-020-01037-0
95. Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2:134–40. doi: 10.1007/s13340-011-0032-0
96. Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014;30(5):775–84. doi: 10.1185/03007995.2013.874989
97. Liu P-Y, Lin L-Y, Lin H-J, et al. Pitavastatin and Atorvastatin Double‑Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study). PLOS ONE. 2013;8(10):e76298. doi: 10.1371/journal.pone.0076298
98. Matsubara T, Naruse K, Arakawa T, et al. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: The PREMIUM Study. J Cardiol. 2012;60(5):389–94. doi: 10.1016/j.jjcc.2012.07.012
99. Hong YJ, Jeong MH, Bae JH, et al. Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II. Korean J Intern Med. 2017;32(4):656–67. doi: 10.3904/kjim.2016.016
100. Vallejo-Vaz AJ, Seshasai SRK, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(12):409–18. doi: 10.1016/j.atherosclerosis.2015.06.001
101. Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiology and drug safety. 2016;25(10):1131–49. doi: 10.1002/pds.4020
102. Choi JY, Choi CU, Hwang S-Y, et al. Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol. 2018;122(6):922–8. doi: 10.1016/j.amjcard.2018/06.017
103. Liu W-T, Lin C, Tsai M-C, et al. Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study. Biomedicines. 2020;8(11):499. doi: 10.3390/biomedicines8110499
104. Wang Y, Fu X, Gu X, et al. Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. Am J Cardiovasc Dis. 2017;7(4):89–96.
105. Lee H-Y, Han K-H, Chung W-B, et al. Safety and Efficacy of Pitavastatin in Patients with Impaired Glucose Tolerance and hyperlipidemia: randomized, open-labeled, multicentered, Phase IV Study. Clinical Therapeutics. 2020;42(10):2036–48. doi: 10/1016/j.clinthera.2020.07.013
106. Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus:an experimental study. Drug Des Devel Ther. 2015;9:6211–23. doi: 10.2147/DDDT.S87979
107. Chrusciel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208. doi: 10.1016/j.atherosclerosis.2016.07.897
108. Betteridge DJ, Carmena R. The diabetogenic action of statins: mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99–110. doi: 10.1038/nrendo.2015.194
109. Drew BG, Rye KA, Duffy SJ, et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8(4):237–45. doi: 10.1038/nrendo.2011.235
110. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–88. doi: 10.1001/jama.2009.976
111. Wu X, Yu Z, Su W, et al. Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. J Clinic Lipidol. 2017;11(2):362–8. doi: 10.1016/j.jacl.2017.01.009
112. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15(5):269–75. doi: 10.5551/jat.e562
113. Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb. 2009;16(5):546–52. doi: 10.5551/jat.992
114. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open‑label, parallel-group comparison of the tolerability and eff ects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089–101. doi: 10.1016/j.clinthera.2008.05.017
115. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39–45. doi: 10.1016/j.thromres.2007.08.013
116. Arai H, Hiro T, Kimura T, et al. for the JAPAN-ACS Investigators. More Intensive Effect of Intensive Lipid Lowering is associated with Regression of Coronary Atherosclerosis in diabetec Patients With Acute Coronary Syndrome. Sub-Analysis of JAPAN-ACS Study. J Atheroscler Thromb. 2010;17(10):1096–107. doi: 10.5551/jat.5660
117. Zhou X, Wu L, Chen Y, et al. Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas. J Diabetes Investig. 2021;12(7):1278–86. doi: 10.1111/jdi.13472
118. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolernia: LIVES study and subanalysis. Expect Rev Cardiovasc Ther. 2011;9(5):555–62. doi: 10.1586/ERS.11.47
119. Tarim BA, Fici F, Tengiz I, et al. Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study. Yonsei Med J. 2023;64(3):175–80. doi: 10.3349/ymj.2022.0287
120. Huang C, Huang Y, Hsu B. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. Diabetes Investig. 2016;7:769–76. doi: 10.1111/jdi.12483
121. Aberg JA, Sponseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised,double-blind, superiority trial. Lancet HIV. 2017;4(7):e284–e294. doi: 10.1016/S2352-3018(17)30075-9
122. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687–99. doi: 10.1056/NEJMoa2304146
123. Vergallo R, Patrono C. Cardiovascular disease prevention in people living with HIV: from REPRIEVE to a statin of grace. Eur Heart J. 2023;44(41):4308–9. doi: 10.1093/eurheartj/ehad594
124. Hoffmann U, Lu MT, Olalere D, et al. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019;212:1–12. doi: 10.1016/j.ahj.2019.02.011

________________________________________________

Авторы

М.Г. Бубнова*¹, А.С. Галявич², М.В. Ежов³, Д.М. Аронов¹, Н.Н. Виноградова⁴, Г.Р. Галстян⁵, В.С. Гуревич^6–8, Ю.А. Карпов³, Н.А. Козиолова⁹, Е.Д. Космачева^10,11, Г.В. Матюшин¹², И.В. Сергиенко³, А.Е. Филиппов⁶, Ю.Ш. Халимов¹³

¹Национальный медицинский исследовательский центр терапии и профилактической медицины, Москва, Россия;
²Казанский государственный медицинский университет, Казань, Россия;
³Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова, Москва, Россия;
⁴Клиническая больница № 1 (Волынская), Москва, Россия;
⁵Национальный медицинский исследовательский центр эндокринологии, Москва, Россия;
⁶Санкт-Петербургский государственный университет, Санкт-Петербург, Россия;
⁷Северо-Западный государственный медицинский университет им. И.И. Мечникова, Санкт-Петербург, Россия;
⁸Северо-Западный окружной научно-клинический центр им. Л.Г. Соколова, Санкт-Петербург, Россия;
⁹Пермский государственный медицинский университет им. акад. Е.А. Вагнера, Пермь, Россия;
¹⁰Научно-исследовательский институт — Краевая клиническая больница № 1 им. профессора С.В. Очаповского, Краснодар, Россия;
¹¹Кубанский государственный медицинский университет, Краснодар, Россия;
¹²Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого, Красноярск, Россия;
¹³Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербург, Россия
*mbubnova@gnicpm.ru

________________________________________________

Marina G. Bubnova*¹, Albert S. Galyavich², Marat V. Ezhov³, David M. Aronov¹, Natalia N. Vinogradova⁴, Gagik R. Galstyan⁵, Viktor S. Gurevich^6–8, Yuri A. Karpov³, Natalia A. Koziolova⁹, Elena D. Kosmacheva¹⁰^,11, Gennady V. Matyushin¹², Igor V. Sergienko³, Alexander E. Filippov⁶, Iurii Sh. Khalimov¹³

¹National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia;
²Kazan State Medical University, Kazan, Russia;
³National Medical Research Center of Cardiology named after Academician E.I. Chazova, Moscow, Russia;
⁴Clinical Hospital No. 1 (Volynskaya), Moscow, Russia;
⁵National Medical Research Center for Endocrinology, Moscow, Russia;
⁶St. Petersburg State University, Saint Petersburg, Russia;
⁷Mechnikov Northwestern State Medical University, Saint Petersburg, Russia;
⁸North-Western District Scientific and Clinical Center named after L.G. Sokolov, St. Petersburg, Russia;
⁹Perm State Medical University named after E.A. Wagner, Perm, Russia;
¹⁰Scientific Research Institute — Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky, Krasnodar, Russia;
¹¹Kuban State Medical University, Krasnodar, Russia;
¹²Professor Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia;
¹³Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
*mbubnova@gnicpm.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.